Biomarkers previously described as having potential predictive value in HNSCC tumors treated with ICB were then explored: TMB (FDA-approved for the use of ICB in solid tumors), PD-L1 CPS, and intratumoral T cell infiltration (9, 14, 16). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.